In 2014 Bioarray pioneered the application of next generation sequencing (NGS) for Preimplantation Genetic Testing (termed PGS & PGD at the time). Bioarray firstly integrated informativity testing, monogenic-disease diagnosis and aneuploidy screening (i.e. PGT-M workup + PGT-M + PGT-A) in a single fast robust NGS workflow, providing unparalleled benefits to patients.
Now it is possible to use NGS technology for PGT allowing not only to select embryos with a higher probability of implantation and thus drastically improve the IVF success rates, but also to use it as a diagnostic tool for couples at higher risk of having children with genetic conditions.
NEW PGT-A CE-IVD mark
Bioarray's PGT-A is nowadays an in vitro diagnostic test, based on the NGS platform we use which achieved the CE-IVD mark. This endorses our NGS approach over other research use only PGT-A tests.
Bioarray performs PGT with the three kinds of cells typically biopsied by IVF labs: polar bodies, day-3 embryo biopsy (blastomeres) and day-5 blastocyst biopsy (trophoectoderm). The latter allowing for mosaicism assessment thanks to NGS sensitivity.
Bioarray launched this new NGS testing after conducting an extensive validation study, based on the comparison of PGT-A results by NGS to well established aCGH, with more than 100 embryos diagnosed and 100% diagnosis correspondence by both techniques.
The PGT-A Premium is our most comprehensive PGT-A test. It allows selecting the most viable embryos obtained in the in vitro fertilization (IVF) procedure, increasing the accuracy and confidence for embryo transfer.
It allows analyzing, in addition to aneuploidies, more than 800 SNPs in the genome.
SNP analysis increases the capabilities of the PGT-A.
Allows to select the most viable embryos increasing the chances of IVF success
Avoids the mixing of embryos, thus giving tranquillity & security to the parents
DETECTION OF HAPLOID OR TRIPLOID EMBRYOS
Allows to recognise 2PN euploid embryos that otherwise would be discarded based on an initial 0PN/1PN/3PN post-fertilization observation
ORIGIN OF ANEUPLOIDY
Determination of maternal or paternal origin of aneuploidies to guide future decisions
|Increased number of reported euploid embryos
|Powered by Artificial Intelligence
|Better clinical results
If you would like to request some more information, you can fill the contact form and send us a message.